Bethanechol (DB01019): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Bethanechol is a synthetic choline ester classified as a direct-acting parasympathomimetic agent. It functions as a selective muscarinic receptor agonist, mimicking the effects of the endogenous neurotransmitter acetylcholine on target organs. Synthesized in 1935, bethanechol's therapeutic utility is predicated on two key molecular features: its high affinity for muscarinic receptors with negligible activity at nicotinic receptors, and its structural resistance to hydrolysis by cholinesterase enzymes.[1] This resistance confers a significantly longer duration of action compared to acetylcholine, making it a viable therapeutic agent.

The primary mechanism of action involves the stimulation of postganglionic muscarinic receptors, particularly the M3 subtype located on the smooth muscle of the urinary bladder and gastrointestinal tract.[3] This action increases the tone of the detrusor muscle, promoting bladder contraction and micturition, and enhances gastrointestinal motility. Consequently, bethanechol holds FDA approval for the treatment of acute postoperative and postpartum non-obstructive urinary retention, as well as for neurogenic atony of the bladder with retention.[5] Its pro-motility effects also support its off-label use in conditions such as gastroesophageal reflux disease (GERD).[8]

The pharmacokinetic profile of bethanechol is characterized by a rapid onset of action following oral or subcutaneous administration. A critical feature of its structure, a permanently charged quaternary ammonium group, prevents it from crossing the blood-brain barrier, thereby confining its activity to the peripheral nervous system and eliminating central nervous system side effects.[1] Notably, there is a significant gap in the scientific literature regarding its metabolism and excretion, with authoritative sources indicating these pathways are not well understood.[3]

The safety profile of bethanechol is a direct extension of its cholinergic pharmacology. Adverse effects, such as salivation, abdominal cramping, hypotension, and bronchoconstriction, are predictable consequences of generalized muscarinic stimulation.[10] Its use is contraindicated in patients with conditions that would be dangerously exacerbated by parasympathetic activation, including mechanical bladder or GI obstruction, asthma, peptic ulcer disease, and significant cardiovascular disease.[2] While bethanechol has been a cornerstone in managing specific urological disorders for decades, emerging research into its potential applications in neonatal respiratory conditions and as an adjuvant in oncology suggests its therapeutic relevance continues to evolve.[12]

Chemical Identity and Physicochemical Properties

The precise identification and characterization of a pharmaceutical agent's chemical and physical properties are fundamental to understanding its behavior, formulation, and biological activity. Bethanechol is a well-defined small molecule with a consistent profile across numerous chemical and drug databases.

Nomenclature and Synonyms

Bethanechol is the established generic name for the active pharmaceutical ingredient.[4] It is most commonly formulated and administered as a salt, Bethanechol Chloride.[1] The drug has been marketed under various brand names, including Urecholine, Duvoid, Myotonachol, and Urocarb, although some brand name formulations are no longer commercially available in certain regions.[2]

Its chemical structure is systematically described by the International Union of Pure and Applied Chemistry (IUPAC) as 2-carbamoyloxypropyl(trimethyl)azanium or 2-(Carbamoyloxy)-N,N,N-trimethylpropan-1-aminium.[1] The name bethanechol itself is a reference to its structure as the urethane of beta-methylcholine.[2] A variety of synonyms are used in scientific literature and databases, including Carbamyl-β-methylcholine, (2-hydroxypropyl)trimethylammonium carbamate, and liberan.[2]

Chemical Identifiers and Formula

The compound is unambiguously identified by a set of standardized codes. The CAS (Chemical Abstracts Service) Registry Number for the active bethanechol moiety is 674-38-4, while the number for the more commonly used chloride salt is 590-63-6.[1] This distinction is crucial for precision in chemical synthesis and pharmaceutical formulation. Its unique DrugBank Accession Number is DB01019.[1]

The molecular formula for the active cationic moiety is $C_{7}H_{17}N_{2}O_{2}^{+}$.[1] This corresponds to a monoisotopic mass of 161.129 g/mol and an average molecular weight of approximately 161.22 g/mol.[2] The formula for bethanechol chloride is $C_{7}H_{17}ClN_{2}O_{2}$, with a molecular weight of 196.68 g/mol.[15]

Structural Information

The molecular structure of bethanechol is represented by the Simplified Molecular Input Line Entry System (SMILES) string CC(C[N+](C)(C)C)OC(=O)N.[1] Its corresponding International Chemical Identifier Key (InChIKey) is NZUPCNDJBJXXRF-UHFFFAOYSA-O, a hashed representation that serves as a digital fingerprint for the molecule.[1]

The structure contains a permanently charged quaternary ammonium ion, [N+](C)(C)C. This structural feature is the primary determinant of the drug's overarching pharmacological profile. The positive charge at physiological pH renders the molecule highly polar, which critically governs its distribution within the body. Specifically, this charge prevents the molecule from passively diffusing across lipid-rich biological membranes, most notably the blood-brain barrier.[1] This confinement to the periphery is directly responsible for its lack of central nervous system (CNS) effects, representing a key structure-activity relationship that defines its clinical utility and safety profile.

Physicochemical Properties

Bethanechol chloride is a white, hygroscopic crystalline solid that emits a slight amine-like odor.[16] It is freely soluble in water, with one gram dissolving in approximately 0.6 mL of water, and is also soluble in alcohol.[16] The melting point of the chloride salt is in the range of 217–221 °C.[1] Aqueous solutions are relatively stable and can be sterilized by autoclaving.[16]

The molecule's properties align well with established criteria for orally bioavailable drugs, known as Lipinski's Rule-of-Five. It has 0 violations of these rules, with a molecular weight under 500, a calculated logarithm of the octanol-water partition coefficient (XLogP) of -0.52, 3 hydrogen bond acceptors, and 1 hydrogen bond donor, suggesting favorable characteristics for absorption after oral administration.[19]

The comprehensive chemical and physical data for bethanechol are summarized in Table 2.1. The high degree of concordance for key identifiers such as the CAS number and InChIKey across multiple independent and authoritative databases (e.g., DrugBank, PubChem, FDA) provides a strong validation of the compound's structural identity and serves as a reliable foundation for all subsequent pharmacological and clinical analysis.[1]

Table 2.1: Comprehensive Identifiers and Physicochemical Properties of Bethanechol

Property	Value	Source(s)
Nomenclature
Generic Name	Bethanechol	4
Common Salt	Bethanechol Chloride	1
IUPAC Name	2-carbamoyloxypropyl(trimethyl)azanium	1
Brand Names	Urecholine, Duvoid, Myotonachol	2
Identifiers
DrugBank ID	DB01019	2
CAS Number (Moiety)	674-38-4	1
CAS Number (Chloride Salt)	590-63-6	1
UNII	004F72P8F4	1
Chemical Formula & Weight
Molecular Formula (Moiety)	$C_{7}H_{17}N_{2}O_{2}^{+}$	1
Molecular Weight (Moiety)	161.22 g/mol	19
Molecular Formula (Chloride)	$C_{7}H_{17}ClN_{2}O_{2}$	22
Molecular Weight (Chloride)	196.68 g/mol	15
Structural Information
SMILES	CC(C[N+](C)(C)C)OC(=O)N	1
InChIKey	NZUPCNDJBJXXRF-UHFFFAOYSA-O	1
Physicochemical Properties
Physical Description	White, hygroscopic crystalline solid	1
Melting Point (Chloride)	217–221 °C	1
Water Solubility	Freely soluble	16
Topological Polar Surface Area	52.32 Ų	19
Lipinski's Rule Violations	0	19

Pharmacology and Mechanism of Action

The therapeutic effects and adverse reaction profile of bethanechol are direct consequences of its interaction with the autonomic nervous system. A thorough understanding of its pharmacology is essential for its safe and effective clinical use.

Drug Classification

Bethanechol is classified as a direct-acting parasympathomimetic (or cholinergic) agent.[6] It is a synthetic choline carbamate, structurally related to the endogenous neurotransmitter acetylcholine.[2] Its primary pharmacological identity is that of a muscarinic receptor agonist, meaning it binds to and activates muscarinic acetylcholine receptors, thereby mimicking the "rest and digest" functions of the parasympathetic nervous system.[1]

Molecular Mechanism of Action

Bethanechol exerts its effects by directly stimulating postganglionic muscarinic receptors located on the surface of effector cells.[3] This action initiates a cascade of intracellular signaling events that produce a physiological response characteristic of parasympathetic nerve stimulation.

Receptor Subtype Activity and Selectivity

There are five known subtypes of muscarinic receptors ($M_{1}$ through $M_{5}$), and bethanechol functions as a non-selective agonist at all of them.[3] However, the clinical effects of the drug are primarily dictated by its actions on specific subtypes in key tissues:

• $M_{3}$ Receptors: These are the most clinically relevant targets for bethanechol's therapeutic effects. They are densely expressed on the smooth muscle of the urinary bladder (the detrusor muscle) and the gastrointestinal tract, as well as on exocrine glands.[3] Agonism at $M_{3}$ receptors leads to smooth muscle contraction and increased glandular secretions.
• $M_{1}$ Receptors: Found on gastric parietal cells, their stimulation by bethanechol contributes to increased gastric motility and tone.[3]
• $M_{2}$ Receptors: Predominantly located in the heart (sinoatrial and atrioventricular nodes), their activation is responsible for the primary cardiovascular side effects of bethanechol, namely bradycardia and slowed atrioventricular conduction.[3]

A crucial aspect of bethanechol's molecular profile is its high selectivity for muscarinic receptors over nicotinic receptors.[1] This selectivity is clinically important because it avoids the effects associated with nicotinic receptor activation, such as skeletal muscle tremors, fasciculations, and stimulation of autonomic ganglia.

Resistance to Cholinesterase Hydrolysis

The therapeutic viability of bethanechol stems from a key innovation in its chemical design compared to the natural ligand, acetylcholine. Acetylcholine is an ineffective systemic drug because it is almost instantaneously hydrolyzed and inactivated by the enzyme acetylcholinesterase.[25] Bethanechol, by contrast, possesses a carbamate ester group instead of an acetate ester, which makes it resistant to degradation by cholinesterase.[1] This chemical modification was a deliberate design choice to overcome the profound pharmacokinetic limitations of the endogenous neurotransmitter. The result is a molecule with a significantly more prolonged duration of action, allowing it to exert sustained therapeutic effects following administration.[2]

Pharmacodynamics (Physiological Effects)

As a global muscarinic agonist, bethanechol produces a wide range of physiological effects throughout the body. The clinical utility of the drug is fundamentally a matter of balancing its desired therapeutic effects, which are primarily mediated by $M_{3}$ receptors, against its dose-limiting side effects, which arise from the stimulation of muscarinic receptors ($M_{1}$, $M_{2}$, and $M_{3}$) in other organ systems. This balance defines its therapeutic window and necessitates careful, individualized dosing.

• Genitourinary Tract: The primary therapeutic effect of bethanechol is on the urinary bladder. It increases the tone and contractile force of the detrusor muscle, leading to an increase in intravesical pressure. This produces a contraction that is typically strong enough to initiate micturition and promote complete bladder emptying in patients with functional retention.[10]
• Gastrointestinal Tract: Bethanechol stimulates smooth muscle throughout the GI tract, increasing gastric tone, enhancing the amplitude of peristaltic contractions, and accelerating gastric emptying.[2] This forms the basis for its off-label use in conditions like GERD and gastroparesis.[14]
• Cardiovascular System: Stimulation of cardiac $M_{2}$ receptors leads to negative chronotropic (decreased heart rate) and dromotropic (decreased conduction velocity) effects.[3] Stimulation of $M_{3}$ receptors on vascular endothelium can cause vasodilation, leading to a drop in blood pressure (hypotension) and cutaneous flushing.[3]
• Exocrine Glands and Other Systems: Bethanechol is a potent secretagogue, increasing secretions from salivary, lacrimal, and sweat glands, leading to salivation, tearing, and diaphoresis.[10] In the eyes, it causes miosis (pupillary constriction). In the respiratory system, it can cause constriction of bronchial smooth muscle, which can be dangerous in patients with asthma.[10]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of bethanechol describes its journey through the body and is critical for determining appropriate dosing regimens and administration routes. While some aspects of its ADME are well-documented, significant knowledge gaps persist, particularly concerning its metabolic fate.

Absorption and Onset of Action

Bethanechol can be administered orally or via subcutaneous injection, with each route having a distinct pharmacokinetic profile that dictates its clinical use.

• Oral Administration: When taken orally, bethanechol's effects on the urinary and gastrointestinal tracts typically begin within 30 to 90 minutes.[3] Maximum effectiveness is generally reached between 60 and 90 minutes post-administration.[3] The duration of action for a standard therapeutic dose is relatively short, lasting approximately one hour.[3] This short duration is the direct pharmacological reason for its frequent dosing schedule of three to four times daily. Larger oral doses (300–400 mg) have been reported to extend the duration of effect for up to six hours.[3] Administration on an empty stomach (one hour before or two hours after meals) is recommended to minimize the incidence of nausea and vomiting.[4]
• Subcutaneous Administration: This route produces a much more rapid and intense physiological response compared to oral administration.[3] The onset of action occurs within 5 to 15 minutes, with peak therapeutic effects observed in 15 to 30 minutes. The duration of action following a subcutaneous injection is approximately two hours.[3] This route is typically reserved for situations requiring a more immediate and potent effect.

The stark differences in the pharmacokinetic profiles between the two routes are summarized in Table 4.1, providing a clear basis for clinical decision-making.

Table 4.1: Comparative Pharmacokinetic Profile of Bethanechol by Route of Administration

Pharmacokinetic Parameter	Oral Route	Subcutaneous Route
Onset of Action	30–90 minutes	5–15 minutes
Time to Peak Effect	60–90 minutes	15–30 minutes
Duration of Action	~1 hour (up to 6 hours with large doses)	~2 hours
Data compiled from sources.3

Distribution

The distribution of bethanechol is severely restricted by its molecular structure. As previously noted, the presence of a permanently charged quaternary amine makes the molecule highly hydrophilic and prevents it from crossing the lipid-rich blood-brain barrier.[1] This is a defining characteristic of the drug, effectively confining its pharmacological actions to the peripheral nervous system and preventing any direct effects on the central nervous system.[3]

Metabolism and Excretion

A critical review of the available literature reveals a significant and persistent knowledge gap regarding the metabolism and excretion of bethanechol. Multiple authoritative sources, including the National Center for Biotechnology Information's StatPearls resource, explicitly state that the metabolic breakdown pathways and elimination mechanisms of bethanechol have not been extensively studied or fully understood.[3] This is a remarkable finding for a drug that has been in clinical use for over 80 years.

This uncertainty is contrasted by a statement from one source suggesting the drug "undergoes limited metabolism and is largely excreted unchanged in the urine".[33] However, this claim is not substantiated by primary pharmacokinetic studies within the provided materials and stands in direct opposition to the more cautious and prevalent view that these processes remain uncharacterized. An expert assessment must prioritize the consensus from clinical pharmacology resources, which acknowledge the lack of definitive data.

This major research gap has direct clinical consequences. For instance, the absence of clear metabolic data means that no specific dosage adjustment guidelines can be provided for patients with hepatic impairment.[28] While it is noted that no dosage adjustment is needed for renal impairment, the scientific basis for this recommendation is unclear without a complete understanding of the drug's excretion pathways.[28] This uncertainty underscores a critical need for modern pharmacokinetic studies to fully characterize the disposition of bethanechol in the human body.

Clinical Applications and Therapeutic Efficacy

Bethanechol occupies a specific niche in modern pharmacotherapy, with well-established indications for conditions involving smooth muscle atony. Its use is also being explored in several novel therapeutic areas.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved bethanechol for the treatment of specific urological conditions where there is a functional, rather than mechanical, impairment of bladder emptying.[6]

• Acute Postoperative and Postpartum Non-obstructive Urinary Retention: This is the primary indication for bethanechol. Following surgery (especially abdominal or pelvic procedures) or childbirth, bladder function can be temporarily impaired due to the effects of anesthesia, neuronal inhibition, or overdistension. Bethanechol helps to restore normal detrusor muscle tone and facilitate urination.[1]
• Neurogenic Atony of the Urinary Bladder with Retention: In certain neurological conditions, such as diabetic neuropathy or spinal cord injury, the nerves controlling the bladder may be damaged, leading to an atonic (flaccid) bladder that cannot contract effectively. Bethanechol is used to stimulate detrusor contraction and improve bladder emptying in these patients.[3]

Across all approved indications, the "non-obstructive" caveat is the single most important diagnostic criterion for its use. Before initiating therapy, it is imperative to rule out any physical blockage of the urinary tract (e.g., prostatic hypertrophy, urethral stricture).[2] Applying a powerful contractile stimulant against a mechanical obstruction can lead to dangerous increases in pressure, potentially causing vesicoureteral reflux or, in extreme cases, bladder rupture.[3]

Off-Label and Investigational Uses

The pharmacological properties of bethanechol have led to its use and investigation in a variety of other conditions beyond its FDA-approved labels.

• Gastroesophageal Reflux Disease (GERD): Bethanechol has been used off-label to treat GERD by increasing the pressure of the lower esophageal sphincter (LES) and promoting the clearance of acid from the esophagus through enhanced gastric motility.[1]
• Gastric Atony and Adynamic Ileus: It is sometimes used to stimulate gastrointestinal motility in patients with delayed gastric emptying or postoperative ileus.[2]
• Dry Mouth (Xerostomia): As a sialogogue (an agent that promotes salivation), bethanechol can alleviate dry mouth, a side effect of certain medications or radiation therapy for head and neck cancer.[2]
• Tracheobronchomalacia in Preterm Infants: A 2023 retrospective cohort study has provided preliminary evidence that bethanechol may improve the respiratory status of preterm infants with severe bronchopulmonary dysplasia and tracheobronchomalacia, a condition characterized by weakness of the tracheal walls.[13] This represents a novel and potentially significant pediatric application.
• Adjuvant in Pancreatic Cancer Therapy: An ongoing Phase 2 clinical trial (NCT05241249) is actively investigating the use of bethanechol in combination with standard chemotherapy (gemcitabine and nab-paclitaxel) for pancreatic adenocarcinoma.[12] This suggests a potential role for muscarinic agonists in modulating the tumor microenvironment or enhancing the efficacy of cytotoxic agents, expanding the drug's therapeutic reach into oncology.

Dosage and Administration

Dosage of bethanechol must be carefully individualized based on the condition being treated, the route of administration, and the patient's response.[25] The range of dosing regimens is summarized in Table 5.1.

Table 5.1: Dosing Regimens for Bethanechol by Indication and Population

Indication	Patient Population	Route	Recommended Dosage	Source(s)
FDA-Approved
Urinary Retention (Non-obstructive)	Adult	Oral	10–50 mg, 3 to 4 times daily. May titrate hourly from 5-10 mg up to a 50 mg max to find effective dose.	25
Neurogenic Bladder Atony	Adult	Oral	10–50 mg, 3 to 4 times daily.	3
Urinary Retention (Acute)	Adult	Subcutaneous	5 mg, 3 to 4 times daily.	31
Off-Label
GERD	Adult	Oral	25 mg, 4 times daily.	8
Urinary Retention	Pediatric	Oral	0.3–0.6 mg/kg/day, divided into 3 to 4 doses.	8
GERD	Pediatric	Oral	0.3–0.6 mg/kg/day, divided into 4 doses.	8
All oral doses should be taken on an empty stomach (1 hour before or 2 hours after meals).25 Subcutaneous administration is not for intramuscular or intravenous use.35

Comprehensive Safety Profile

The safety profile of bethanechol is well-characterized and is almost entirely predictable from its mechanism of action as a global muscarinic agonist. Adverse events are extensions of its pharmacology, and contraindications are logically derived from conditions that would be exacerbated by parasympathetic stimulation.

Contraindications

The use of bethanechol is absolutely contraindicated in patients with certain pre-existing conditions where cholinergic stimulation would pose a significant risk. These contraindications represent patient groups with no physiological margin for cholinergic error, where a typical side effect could become a life-threatening event.

• Mechanical Obstruction: Contraindicated in the presence of any mechanical obstruction of the gastrointestinal or urinary tract.[2]
• Asthma: Should not be used in patients with latent or active bronchial asthma due to the risk of inducing severe bronchoconstriction.[2]
• Hyperthyroidism: May precipitate atrial fibrillation in hyperthyroid patients.[2]
• Peptic Ulcer Disease: Can increase gastric acid secretion, potentially worsening active ulcers.[2]
• Significant Cardiovascular Disease: Contraindicated in patients with pronounced bradycardia, hypotension, vasomotor instability, coronary artery disease, or recent myocardial infarction.[2]
• Neurological Conditions: Should not be used in patients with epilepsy or Parkinsonism, as it may exacerbate symptoms.[8]
• Recent Surgery: Contraindicated when the structural integrity of the gastrointestinal or bladder wall is in question, such as following recent surgery or anastomosis.[10]

Warnings and Precautions

• Risk of Reflux Infection: A critical safety concern exists in patients with urinary retention. If the bladder sphincter fails to relax concurrently with bethanechol-induced detrusor contraction, urine may be forced retrograde up the ureters into the kidney pelvis. If bacteriuria is present, this can cause a serious reflux infection (pyelonephritis).[3]
• Hypotension: Bethanechol can cause a drop in blood pressure, which may lead to dizziness, lightheadedness, or syncope. This is particularly relevant when patients change posture (orthostatic hypotension). Patients should be advised to rise slowly from a sitting or lying position.[3]
• Pregnancy and Lactation: Bethanechol is classified as Pregnancy Category C. Its safety in pregnancy has not been established, and it should be used only if the potential benefit justifies the potential risk to the fetus. It is unknown if the drug is excreted in human milk, and a decision should be made whether to discontinue the drug or nursing.[29]

Adverse Drug Reactions (ADRs)

Adverse reactions are common, generally mild to moderate, and are dose-dependent. They are more frequent and intense following subcutaneous injection compared to oral administration.[29] The profile of ADRs is a coherent set of symptoms that can be reasoned from the drug's mechanism, not a random list to be memorized.

• Common ADRs:
• Gastrointestinal: Abdominal cramps or discomfort, colicky pain, nausea, vomiting, belching, diarrhea, borborygmi (stomach rumbling), and excessive salivation.[3]
• Genitourinary: Urinary urgency.[10]
• General: Malaise, sweating, and flushing of the skin with a sensation of warmth.[10]
• Nervous System/Special Senses: Headache, lacrimation (tearing), and miosis (pupil constriction).[3]
• Serious ADRs:
• Cardiovascular: A significant fall in blood pressure with reflex tachycardia, heart block, or cardiac arrest.[3]
• Respiratory: Bronchial constriction and precipitation of asthmatic attacks.[11]
• Nervous System: Seizures have been reported, although a causal relationship has not been firmly established.[29]

Management of Overdosage

Overdosage with bethanechol results in a cholinergic crisis. Early signs are an exaggeration of the common adverse effects and include severe abdominal discomfort, excessive salivation, flushing of the skin, sweating, nausea, and vomiting.[25]

The specific antidote for bethanechol toxicity is Atropine Sulfate, a competitive muscarinic receptor antagonist. For adults, the recommended dose is 0.6 mg, administered subcutaneously or intravenously, which can be repeated every two hours as needed based on clinical response. For children, the dose is 0.01 mg/kg (up to a maximum of 0.4 mg).[25]

Clinically Significant Drug Interactions

The drug interaction profile for bethanechol is overwhelmingly pharmacodynamic in nature, involving direct or indirect modulation of the cholinergic system at the receptor level. This observation aligns with the lack of well-defined metabolic pathways for the drug, as a compound that is not significantly metabolized is unlikely to participate in metabolism-based (i.e., pharmacokinetic) drug interactions.[30]

Pharmacodynamic Interactions

Interactions are broadly categorized as either antagonistic (reducing bethanechol's effect) or synergistic (increasing its effect and/or toxicity).

Antagonistic Interactions

• Anticholinergic Agents: This is the most significant class of interacting drugs. Medications with antimuscarinic properties, such as atropine, dicyclomine (an antispasmodic), aclidinium (an inhaled respiratory drug), many tricyclic antidepressants (e.g., amitriptyline, doxepin), and first-generation antihistamines (e.g., diphenhydramine), will directly compete with bethanechol at muscarinic receptors. This competitive antagonism will reduce or abolish the therapeutic effects of bethanechol.[28]
• Sympathomimetic Agents: Drugs that stimulate the sympathetic nervous system, such as decongestants (pseudoephedrine, phenylephrine) and stimulants (amphetamine), can physiologically oppose the effects of bethanechol at sites with dual autonomic innervation, such as the heart and vasculature.[28]

Synergistic/Additive Interactions

• Other Cholinergic Agonists: Co-administration with other direct-acting muscarinic agonists, such as pilocarpine or cevimeline (used for dry mouth), will result in additive cholinergic effects, significantly increasing the risk of adverse reactions and toxicity.[37]
• Cholinesterase Inhibitors: Drugs that inhibit the acetylcholinesterase enzyme, such as those used to treat Alzheimer's disease (donepezil, rivastigmine) or myasthenia gravis (neostigmine), work by increasing the synaptic concentration of acetylcholine. When given with bethanechol, this leads to a potentiation of cholinergic stimulation at the receptor, heightening the risk of side effects.[38]
• Ganglion Blocking Compounds: A specific warning exists for the co-administration of bethanechol with ganglion-blocking agents. This combination can precipitate a critical and severe fall in blood pressure.[10]
• Beta-Blockers: These cardiovascular drugs can also slow the heart rate and may amplify the bradycardic effects of bethanechol, increasing the risk of significant heart rate depression.[30]

A summary of these key interactions is provided in Table 7.1.

Table 7.1: Clinically Significant Drug Interactions with Bethanechol

Interacting Drug/Class	Mechanism of Interaction	Potential Clinical Outcome	Management Recommendation
Anticholinergic Agents (e.g., atropine, dicyclomine, amitriptyline)	Pharmacodynamic Antagonism (Competition at muscarinic receptors)	Decreased or abolished therapeutic effect of bethanechol.	Avoid combination if possible. Monitor for lack of efficacy.
Sympathomimetic Agents (e.g., pseudoephedrine, amphetamine)	Physiological Antagonism (Opposing effects of sympathetic vs. parasympathetic stimulation)	Offset of bethanechol's effects, particularly on the cardiovascular system.	Monitor clinical response (e.g., blood pressure, heart rate).
Cholinesterase Inhibitors (e.g., donepezil, neostigmine)	Pharmacodynamic Synergism (Increased overall cholinergic tone)	Increased risk and severity of cholinergic adverse effects (e.g., bradycardia, diarrhea, salivation).	Use with caution. Monitor closely for signs of cholinergic toxicity.
Other Muscarinic Agonists (e.g., pilocarpine, cevimeline)	Additive Pharmacodynamic Effects	Markedly increased risk of cholinergic toxicity.	Combination is generally not recommended.
Ganglion Blocking Compounds	Synergistic Hypotensive Effect	Critical fall in blood pressure.	Use with extreme caution and intensive monitoring.
Beta-Blockers	Additive Bradycardic Effect	Increased risk of severe bradycardia or heart block.	Monitor heart rate closely.
Data compiled from sources.10

Use in Special Populations

The use of bethanechol requires special consideration in certain patient populations due to potential for altered pharmacodynamics, increased risk of adverse effects, or lack of safety data.

Pregnancy and Lactation

• Pregnancy: Bethanechol is designated as Pregnancy Category C by the FDA.[29] This indicates that animal reproduction studies have not been conducted, and there are no adequate and well-controlled studies in pregnant women. Therefore, bethanechol should be administered to a pregnant woman only if it is clearly needed and the potential benefits outweigh the unknown risks to the fetus.[29]
• Lactation: It is not known whether bethanechol is excreted in human milk.[29] Because many drugs are excreted in breast milk and due to the potential for serious adverse reactions in nursing infants, a clinical decision must be made. This involves weighing the importance of the drug to the mother against the potential risk to the infant, and may necessitate either discontinuing the drug or discontinuing breastfeeding.[29] There are reports of abdominal pain and diarrhea in infants exposed to bethanechol through breast milk, suggesting that the drug can affect the infant.[35]

Pediatric Use

The safety and effectiveness of bethanechol in pediatric patients have not been formally established through rigorous clinical trials, and it is not FDA-approved for this population.[29] Despite this, it is used off-label in children and adolescents for conditions such as non-obstructive urinary retention and GERD.[8] When used in this population, dosing is typically based on body weight (mg/kg), and special care and close monitoring are required.[10]

Geriatric Use

Older adults may exhibit increased sensitivity to the effects of bethanechol. They may experience sensory responses in the bladder, such as urgency, at lower bladder volumes compared to younger adults.[3] Furthermore, the geriatric population is often at a higher risk for the adverse cardiovascular and neurological effects of the drug, including hypotension, bradycardia, dizziness, and lightheadedness. These side effects can significantly increase the risk of falls and related injuries in frail or elderly patients.[17] Therefore, cautious dosing and vigilant monitoring for adverse events are essential when prescribing bethanechol to older adults.

Conclusion and Future Directions

Bethanechol is a long-established parasympathomimetic agent whose clinical role is defined by its potent and selective muscarinic agonist activity. Its primary utility in managing non-obstructive urinary retention and neurogenic bladder atony is a direct result of its ability to stimulate detrusor muscle contraction. The drug's rational design, specifically its resistance to cholinesterase and its inability to cross the blood-brain barrier, underpins its therapeutic viability and favorable peripheral safety profile. The adverse effects and contraindications are well-understood and are predictable extensions of its core pharmacology, allowing for effective risk mitigation through careful patient selection and monitoring.

Despite its long history of use, this comprehensive review highlights critical areas for future investigation and development that could refine and potentially expand the role of bethanechol in medicine.

• Pharmacokinetic Research: The most glaring deficiency in the current body of knowledge is the lack of definitive data on the metabolism and excretion of bethanechol. This is a significant gap for a drug that has been in clinical use for nearly a century. Modern, rigorous pharmacokinetic studies are urgently needed to fully characterize its absorption, distribution, metabolism, and excretion (ADME) profile. Such studies would provide the scientific basis for developing evidence-based dosing guidelines for patients with renal and hepatic impairment, who are currently managed without specific recommendations.
• Investigational Applications: The emerging research into bethanechol's use in novel contexts is promising. The preliminary findings in neonatal tracheobronchomalacia and the ongoing Phase 2 trial in pancreatic cancer suggest a potential renaissance for this molecule beyond its traditional urological applications. Future research should focus on elucidating the specific mechanisms underlying these potential benefits—for example, whether bethanechol's effects in oncology are related to modulating the tumor microenvironment or improving drug delivery. Rigorous, prospective, randomized controlled trials are essential to validate these preliminary findings and establish efficacy and safety in these new patient populations.
• Formulation Development: The clinical utility of bethanechol for chronic conditions is limited by its short duration of action, which necessitates a frequent dosing schedule of three to four times per day. This can be a significant barrier to patient adherence. The development of a modern, controlled-release oral formulation could provide more stable plasma concentrations over a 24-hour period. Such a formulation would improve patient convenience, enhance adherence, and potentially offer a more consistent therapeutic effect, thereby strengthening its utility in the long-term management of conditions like chronic neurogenic bladder.

In conclusion, bethanechol remains a valuable and clinically relevant medication for its specific, well-defined indications. However, its full potential may yet be untapped. Addressing the fundamental gaps in its pharmacokinetic profile and rigorously exploring its novel therapeutic applications will ensure that this venerable drug can continue to contribute to patient care in the 21st century.

Works cited

1. Bethanechol | C7H17N2O2+ | CID 2370 - PubChem - NIH, accessed October 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Bethanechol
2. Bethanechol - Wikipedia, accessed October 22, 2025, https://en.wikipedia.org/wiki/Bethanechol
3. Bethanechol - StatPearls - NCBI Bookshelf, accessed October 22, 2025, https://www.ncbi.nlm.nih.gov/books/NBK560587/
4. Bethanechol: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 22, 2025, https://go.drugbank.com/drugs/DB01019
5. Non-obstructive postpartum urinary retention | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/indications/DBCOND0138338
6. www.ncbi.nlm.nih.gov, accessed October 22, 2025, https://www.ncbi.nlm.nih.gov/books/NBK560587/#:~:text=Bethanechol%20is%20an%20FDA%2Dapproved,to%20the%20parasympathomimetic%20drug%20class.
7. Bethanechol | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/articles/A232905
8. Bethanechol: Overactive Bladder Uses, Warnings, Side Effects, Dosage - MedicineNet, accessed October 22, 2025, https://www.medicinenet.com/bethanechol/article.htm
9. www.medicinenet.com, accessed October 22, 2025, https://www.medicinenet.com/bethanechol/article.htm#:~:text=Bethanechol%20is%20a%20medication%20approved,gastroesophageal%20reflux%20disease%20(GERD).
10. Bethanechol - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed October 22, 2025, https://www.pediatriconcall.com/drugs/bethanechol/329
11. What is the mechanism of Bethanechol Chloride? - Patsnap Synapse, accessed October 22, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-bethanechol-chloride
12. Bethanechol Recruiting Phase 2 Trials for Pancreatic Cancer Other | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/drugs/DB01019/clinical_trials?conditions=DBCOND0028482&phase=2&purpose=other&status=recruiting
13. The effect of bethanechol on tracheobronchomalacia in preterm infants with bronchopulmonary dysplasia: a retrospective cohort study - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/37848605/
14. Bethanechol: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 22, 2025, https://www.rxlist.com/bethanechol/generic-drug.htm
15. Bethanechol chloride - KEGG DRUG, accessed October 22, 2025, https://www.kegg.jp/entry/D01000
16. Bethanechol Chloride, accessed October 22, 2025, https://www.drugfuture.com/chemdata/bethanechol-chloride.html
17. Bethanechol: Uses, Side Effects, Warnings & More - GoodRx, accessed October 22, 2025, https://www.goodrx.com/bethanechol/what-is
18. BETHANECHOL | 674-38-4 - ChemicalBook, accessed October 22, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3733958.htm
19. bethanechol - Drug Central, accessed October 22, 2025, https://drugcentral.org/drugcard/358
20. CAS 674-38-4: Bethanechol - CymitQuimica, accessed October 22, 2025, https://cymitquimica.com/cas/674-38-4/
21. BETHANECHOL - precisionFDA, accessed October 22, 2025, https://precision.fda.gov/ginas/app/ui/substances/6ac026de-bfa5-460a-b3f8-44099dc43cc7
22. Compound: BETHANECHOL CHLORIDE (CHEMBL1768) - ChEMBL - EMBL-EBI, accessed October 22, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1768
23. bethanechol | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=297
24. BETHANECHOL - precisionFDA, accessed October 22, 2025, https://precision.fda.gov/ginas/app/ui/substances/004F72P8F4
25. BETHANECHOL CHLORIDE tablet - DailyMed, accessed October 22, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78c09ab4-35fc-4cad-a133-d7ad8ae1fec3
26. bethanechol | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297
27. www.ncbi.nlm.nih.gov, accessed October 22, 2025, https://www.ncbi.nlm.nih.gov/books/NBK560587/#:~:text=Mechanism%20of%20Action,-Bethanechol%20exerts%20its&text=Bethanechol%20also%20acts%20on%20the,may%20reestablish%20diminished%20rhythmic%20peristalsis.
28. Urecholine - Drug Summary - PDR.Net, accessed October 22, 2025, https://www.pdr.net/drug-summary/Urecholine-bethanechol-chloride-801
29. Label: BETHANECHOL CHLORIDE tablet - DailyMed, accessed October 22, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=572c42de-3e85-42b1-a8af-8cebdb9153f9
30. Bethanechol | Drug Lookup | Pediatric Care Online | American ..., accessed October 22, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5611/Bethanechol
31. Bethanechol (oral route, subcutaneous route) - Side effects ..., accessed October 22, 2025, https://www.mayoclinic.org/drugs-supplements/bethanechol-oral-route-subcutaneous-route/description/drg-20062277
32. What is the recommended dosage and treatment protocol for Bethanechol (a muscarinic agonist) in patients with urinary retention issues? - Dr.Oracle, accessed October 22, 2025, https://www.droracle.ai/articles/311385/bethanechol
33. Clinical Profile of Bethanechol Chloride 50mg Tablet - GlobalRx, accessed October 22, 2025, https://www.globalrx.com/articles?article=bethanechol-50mg-tablet-profile&product_id=42353
34. Bethanechol: MedlinePlus Drug Information, accessed October 22, 2025, https://medlineplus.gov/druginfo/meds/a682849.html
35. Bethanechol (Urecholine, Duvoid), accessed October 22, 2025, https://glowm.com/resources/glowm/cd/pages/resources/Pharmacy/bethan.htm
36. Bethanechol: Pediatric Medication - Memorial Sloan Kettering Cancer Center, accessed October 22, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/bethanechol
37. Showing BioInteractions for Bethanechol (DB01019) | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/drugs/DB01019/biointeractions
38. Urecholine (bethanechol) dosing, indications, interactions, adverse effects, and more, accessed October 22, 2025, https://reference.medscape.com/drug/urecholine-bethanechol-343056
39. What is Bethanechol Chloride used for? - Patsnap Synapse, accessed October 22, 2025, https://synapse.patsnap.com/article/what-is-bethanechol-chloride-used-for
40. Bethanechol Tablets: Uses & Side Effects - Cleveland Clinic, accessed October 22, 2025, https://my.clevelandclinic.org/health/drugs/19003-bethanechol-tablets